Description

Cytarabine Hydrochloride (CAS No. 69-74-9) is a highly potent nucleoside analog and antimetabolite, widely recognized for its critical role in chemotherapy. With the molecular formula C₉H₁₄ClN₃O₅, this crystalline compound is the hydrochloride salt of cytarabine, a synthetic pyrimidine nucleoside derivative. It functions by inhibiting DNA polymerase during the S-phase of cell division, making it particularly effective against rapidly proliferating cancer cells. This pharmaceutical-grade compound is rigorously tested for purity, stability, and consistency, ensuring optimal performance in research and clinical applications. Suitable for use in in vitro and in vivo studies, Cytarabine Hydrochloride is an essential tool for oncological research, drug development, and molecular biology.

Our Cytarabine Hydrochloride is supplied as a white to off-white powder with ≥98% purity (HPLC), ensuring high reliability for laboratory and industrial applications. Each batch undergoes stringent quality control, including spectroscopic (NMR, IR) and chromatographic (HPLC) validation, to meet USP/EP/BP standards. Store desiccated at 2-8°C for prolonged stability. Available in bulk quantities with customizable packaging options.

Properties

• CAS Number: 69-74-9
• Complexity: 383
• IUPAC Name: 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one;hydrochloride
• InChI: InChI=1S/C9H13N3O5.ClH/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8;/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16);1H/t4-,6-,7+,8-;/m1./s1
• InChI Key: KCURWTAZOZXKSJ-JBMRGDGGSA-N
• Exact Mass: 279.0621982
• Molecular Formula: C9H14ClN3O5
• Molecular Weight: 279.68
• SMILES: C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O.Cl
• Topological: 129
• Monoisotopic Mass: 279.0621982
• Physical Description: Crystals or fluffy white powder.
• Melting Point: 356 to 360 °F
• Solubility: >42 [ug/mL]
• Synonyms: CYTARABINE HYDROCHLORIDE, 69-74-9, Cytosine arabinoside hydrochloride, Cytarabine HCl, 1-beta-D-Arabinofuranosylcytosine hydrochloride, Ara-C hydrochloride, Cytosar hydrochloride, Spongocytidine hydrochloride, Arabitin hydrochloride, Aracytin hydrochloride, Cytarabin hydrochloride, Aracytidine hydrochloride, Arabinosylcytosine hydrochloride, Cytarabine hydrochloride [USAN], U-19920A, CCRIS 4774, Arabinosyl cytosine hydrochloride, EINECS 200-713-9, DTXSID5024891, AI3-52344, 1beta-D-Arabinofuranosylcytosine hydrochloride, NSC-63878, 1beta-D-Arabinofuranosylcytosine monohydrochloride, 33K3DB6591, 1-beta-D-Arabinofuranosylcytosine monohydrochloride, Cytosine, 1-beta-D-arabinofuranosyl-, hydrochloride, Cytosine, 1-beta-D-arabinofuranosyl-, monhydrochloride, Cytosine, 1beta-D-arabinofuranosyl-, monohydrochloride, DTXCID104891, Cytarabine hydrochloride (USAN), Arabinofuranosylcytosine hydrochloride, 2(1H)-Pyrimidinone, 4-amino-1-beta-D-arabinofuranosyl-, monohydrochloride, AC 1075, Cytosine, 1-beta-D-arabinofuranosyl-, monohydrochloride, CYTARABINE HYDROCHLORIDE [WHO-DD], 2(1H)-Pyrimidinone, 4-amino-1-.beta.-D-arabinofuranosyl-, monohydrochloride, 1-.BETA.-D-ARABINOFURANOSYLCYTOSINE MONOHYDROCHLORIDE, Spongocytidine-hydrochloride, NSC63878, Ara-C HCl, Cytosine Arabinosine Hydrochloride, 4-Amino-1-beta-d-arabinofuranosyl-2(1H)-pyrimidinone hydrochloride, 4-AMINO-1-BETA-D-ARABINOFURANOSYL-2(1H)-PYRIMIDINONE MONOHYDROCHLORIDE, 200-713-9, Cytarabine (hydrochloride), Cytosine-1-beta-D-arabinofuranoside hydrochloride, Cytosine beta-D-arabinofuranoside hydrochloride, MFCD00012839, 69-74-9 (HCL), MLS000028466, 29363-79-9, SMR000058432, 4-amino-1-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one hydrochloride, 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;hydrochloride, SR-01000075773, UNII-33K3DB6591, 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one hydrochloride, Opera_ID_1542, Arabinocytidine hydrochloride, SCHEMBL67288, MLS001148147, MLS002207299, CHEMBL1256472, GLXC-15916, Tox21_300488, Tox21_500316, HY-13605A, s5582, AKOS015896936, AKOS015960559, AKOS015995277, CCG-221620, LP00316, NA05780, SCH-900242, CAS-69-74-9, NCGC00093762-01, NCGC00254321-01, NCGC00261001-01, AC-11705, AC-32195, BA164338, Cytarabine hydrochloride – Bio-X trade mark, DB-025611, Cytosine-beta-D-arabinofuranose hydrochloride, EU-0100316, NS00076327, 1-(b-D-Arabinofuranosyl)cytosine hydrochloride, A51105, C 6645, Cytosine beta -D-arabinofuranoside hydrochloride, D03637, 1-(beta-d-arabino-furanosyl)-cytosine hydrochloride, SR-01000075773-1, Q27256279, Cytosine beta-D-arabinofuranoside hydrochloride, crystalline, Cytosine ?-D-arabinofuranoside hydrochloride;Ara-C.hydrochloride, 2(1H)-Pyrimidinone,4-amino-1-b-D-arabinofuranosyl-,hydrochloride (1:1), Arabinocytidine hydrochloride; Arabinosylcytosine hydrochloride; Ara-C hydrochloride, 4-Amino-1-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one hydrochloride, 4-Amino-1-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one hydrochloride(1:x), 4-Amino-1-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-onehydrochloride(1:x), Cytosine ?-D-arabinofuranoside hydrochloride;1-(?-D-Arabinofuranosyl)cytosine hydrochloride;Ara-C.hydrochloride

Cytarabine Hydrochloride is primarily used as an antineoplastic agent in the treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and non-Hodgkin’s lymphoma. It is also employed in research to study mechanisms of DNA synthesis inhibition and chemoresistance. In combination therapies, it enhances the efficacy of other anticancer drugs. Laboratory applications include cell culture studies to evaluate apoptosis and cell cycle arrest.

Safety and Hazards

GHS Hazard Statements

• H317 (100%): May cause an allergic skin reaction [Warning Sensitization, Skin]
• H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]
• H341 (95%): Suspected of causing genetic defects [Warning Germ cell mutagenicity]
• H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

Precautionary Statements

• P203, P261, P264+P265, P272, P280, P302+P352, P305+P351+P338, P318, P321, P333+P317, P337+P317, P362+P364, P405, and P501

Hazard Classes and Categories

• Skin Sens. 1 (100%)
• Eye Irrit. 2 (100%)
• Muta. 2 (95%)
• Repr. 2 (100%)

If you are interested or have any questions, please contact us at support@atomfair.com

Disclaimer: Sold exclusively for laboratory research. Prohibited for commercial use, diagnostics, or human/animal applications. Buyers assume all compliance liability.